Takeda Pharmaceutical Co has responded again to reports that a much-rumoured acquisition of Switzerland’s Nycomed is a done deal, denying that any agreement is in place. For the last week or so, it has been reported that the Japanese drugmaker has agreed a deal to buy privately-owned Nycomed for around one trillion yen, or around $12.3 billion. Just before last weekend, Takeda felt moved to make a statement saying no agreement had been reached.
